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Depot buprenorphine injections for opioid use disorder: Patient
information needs and preferences
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Abstract
Introduction and Aims. There has been significant recent investment in new medications for opioid use disorder, including
buprenorphine depot injections. Patients and professionals need good quality, independent information on medications to help
them make informed treatment decisions. This paper aims to understand patients’ information needs and preferences in relation
to buprenorphine depot injections. Design and Methods. Semi-structured qualitative interviews were conducted with
36 people using opioids (26 men, 10 women; 24–63 years). Twelve participants were currently prescribed daily oral metha-
done; 12 were currently prescribed daily oral buprenorphine; and 12 were using heroin and not in treatment. Interviews were
transcribed, coded and analysed via Iterative Categorisation. Results. Participants asked many questions about depot
buprenorphine injections. These related to: (i) medication purpose and availability; (ii) pharmacology; (iii) evidence base
and effectiveness; (iv) safety and side effects; (v) administration and dosing; and (vi) reducing and ending treatment. Addi-
tionally, participants expressed their information preferences in terms of (i) ‘format’ and (ii) ‘source’. Specifically, they
wanted printed, verbal and electronic materials provided by people in authority, particularly patients who had already had
the medication. Discussion and Conclusions. All potential patients should be offered accessible information on depot
buprenorphine to enable them to consider their options and participate meaningfully in treatment decision making. We recom-
mend that further qualitative research is undertaken to produce informative video material that describes patient experiences of
receiving depot buprenorphine. This should help to balance biomedical knowledge with lay knowledge, so facilitating more
informed discussions when decisions about depot buprenorphine treatment are made. [Neale J, Tompkins CNE, Strang J.
Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug Alcohol
Rev 2019;38:510–518]
Key words: extended release buprenorphine, heroin, opioid, information, qualitative method.
Introduction
‘Medication-assisted treatment’ (MAT) refers to the
use of approved medications, combined with counsel-
ling and behavioural therapies, to provide a
‘whole-patient’ approach to the treatment of substance
use disorders [1]. Medications used in MAT for opioid
use disorder routinely include opioid agonists (e.g.
methadone), partial agonists (e.g. buprenorphine) and
opioid antagonists (e.g. naltrexone) [2]. Historically,
these medications have almost always been taken daily,
in liquid/linctus or tablet//film form, with injectables
occasionally provided to patients who repeatedly fail to
benefit from oral formulations [3]. Opioid agonist
treatment is closely monitored by regulatory authori-
ties and clinicians, and medication consumption is
often physically supervised in a drug treatment or com-
munity pharmacy setting [4].
Research shows that MAT can decrease opioid use,
increase retention in treatment, improve psychosocial
treatment outcomes and reduce drug-related deaths
[1,5,6]. Nonetheless, the use of medications for sub-
stance use disorder is not without challenges. Patients
can become addicted to the agonists themselves, and
there are risks associated with diversion, ‘using on top’
and missed doses [7]. In addition, patients have com-
plained that the process of frequent dosing is
stigmatising, restricts their freedom, and undermines
their quality of life by making it difficult to work, take
a holiday, and participate in other everyday activities
[8–10]. Unsurprisingly, therefore, poor/non-adherence
and treatment dropout are common in MAT [4].
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Global increases in opioid use, alongside poor
adherence to existing medications, have latterly gener-
ated interest and investment in new types of MAT,
including extended release formulations [11–14]. Over
the last decade or so, buprenorphine depot injections
have been developed for subcutaneous administration
[15]. In November 2017, the first depot
buprenorphine product Sublocade™ (RBP-6000) was
approved by the US Food and Drug Administration
(FDA) for monthly administration [16]. In November
2018, two additional products – Buvidal® Weekly and
Buvidal® Monthly (CAM2038) – were approved by
the European Medicines Agency (EMA) for use in
Europe and by the Australian Therapeutic Goods
Administration (TGA) for use in Australia [17,18].
Depot injections provide sustained medication release
and bypass the need for daily dosing. This is expected
to reduce the treatment burden for clinicians and
patients, improve patient adherence, and remove the
risk of diversion [7,11,12,19].
Medications containing buprenorphine partially acti-
vate the body’s opioid receptors but also attach them-
selves more strongly to those receptors than drugs
such as heroin and morphine [7]. This should reduce
opioid withdrawal symptoms and the desire to use opi-
oids without causing the cycle of highs and lows asso-
ciated with opioid use disorder [7,20]. When
administered alone at high doses, buprenorphine is
safer than pure opioid agonists, but will precipitate
opioid withdrawal in individuals who are physically
dependent on full opioid agonists [15,21]. In conse-
quence, care must be taken when initiating
buprenorphine treatment or when switching from
methadone to buprenorphine; it is recommended that
people should taper down their use of pure agonists
prior to making the switch [22]. In addition, anyone
making the transition should be in a state of moderate
withdrawal before taking their first buprenorphine dose
[21].
An increase in MAT options is to be welcomed
but will inevitably make treatment decision making
more complicated [14]. Patients and professionals
will need high quality, clear, independent informa-
tion about depot buprenorphine to help them make
informed choices. Licenses for new medications con-
firm the name of the medication, the health condi-
tion for which it should be used, the recommended
dosage, wanted and unwanted effects, and informa-
tion on using the medicine. Every licensed medicine
also has a Summary of Product Characteristics
(a legal document describing the product’s proper-
ties and the conditions attached to its use) and a
patient information leaflet or PIL (which provides
information on using the medicine safely) [23].
Beyond this, the availability of unbiased information
on new medications tends to be limited, particularly
for patients [24,25].
The pharmaceutical industry is widely considered
incapable of providing non-promotional information
on its products due to inherent financial conflicts of
interest [26]. Reflecting this, direct-to-consumer
advertising (DTCA) is permitted in only a very small
number of countries and has been criticised for provid-
ing poor quality information and generating unneces-
sary medicine use [27]. Within the clinical encounter,
meanwhile, power differentials between the doctor and
patient, and the dominance of biomedical over lay
knowledge, can prevent patients from articulating their
questions and concerns about medications [24,28,29].
Illustrating this, a study of opioid treatment conducted
in 10 European countries found that less than half of
the people using opioids surveyed consulted physicians
or pharmacists for information and most had limited
knowledge of the available MAT options [30].
The aim of this paper is to better understand
patients’ information needs and information prefer-
ences in relation to the new buprenorphine depot
injection formulations. To this end, we address two
specific questions: (i) What questions do potential
patients have about depot buprenorphine? and
(ii) How do potential patients want to receive informa-
tion about depot buprenorphine? We then use the
findings to consider ways of developing accessible
information sources. We will report other important
issues, such as potential patients’ personal willing to
receive depot buprenorphine, separately [authors, in
preparation].
Methods
Data were generated as part of a qualitative study
exploring opioid users’ perceptions of, and willingness
to receive, extended release depot buprenorphine. The
research was funded by Camurus AB, the pharmaceu-
tical company that has developed CAM2038/
Buvidal®. Fieldwork was conducted in Greater
London, UK, between June and October 2018 (just
prior to the regulatory approvals of Buvidal® across
Europe and Australia). Members of a specialist
addiction Service User Research Group (SURG;
https://www.kcl.ac.uk/ioppn/depts/addictions/research/
surg/index.aspx) provided feedback to help shape the
study design, and ethical approval was received from
King’s College London University Research Ethics
Committee with additional approvals granted from
two voluntary sector services.
Recruitment sites included two alcohol and other
drug treatment services, two homeless hostels, and an
Depot buprenorphine and patient information 511
© 2019 The Authors Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other
Drugs
alcohol and other drug peer support service. A quota
sampling strategy was employed to recruit 12 people
currently prescribed oral methadone; 12 people cur-
rently prescribed oral buprenorphine and 12 people
who were using heroin daily but not currently in treat-
ment. These criteria were chosen to include groups of
people using opioids who might be eligible to have a
depot buprenorphine injection; that is, ‘potential
patients’. We anticipated that 36 participants would
enable us to reach an adequate level of data saturation
[31] whilst permitting tentative exploration of any dif-
ferences between the three groups.
Recruitment processes varied slightly between the
five sites to accommodate local service arrangements.
However, they all followed the same basic protocol;
that is, the study researcher (CT) briefed service staff
on the aims and methods. Service staff then
approached people whom they considered to be eligi-
ble, provided them with information about the study,
and solicited permission to pass their contact details to
CT. CT next contacted all interested people,
described the study further, and completed a basic
screening questionnaire to check eligibility. Several
people who could not speak English were excluded at
this point as there were no resources for interpreters.
Otherwise, eligible people were invited to participate in
a semi-structured interview at a time of their choosing.
Prior to interview, written informed consent was
obtained. A topic guide was then used to explore par-
ticipants’ personal circumstances; substance use and
treatment history; views on depot buprenorphine;
interest in receiving depot buprenorphine; factors that
might encourage or discourage receipt of depot
buprenorphine; and information needs and preferences
in relation to depot buprenorphine. To facilitate dis-
cussion, participants received basic verbal information
based on the concept of the depot buprenorphine
product CAM2038/ Buvidal®. This information
included how the medication would be injected under
the skin; how it might release slowly over a period of
7 or 28 days; how it would be administered by a
healthcare professional into the arm, thigh, stomach or
buttock; how the dose would be determined by the
patient and prescriber but could be ‘boosted’ if
needed; and how side effects would be the same as for
oral buprenorphine, although there might be some
additional local discomfort from the injection. Partici-
pants were also shown a prototype depot injection
prefilled syringe device that contained no active
medication.
Interviews took place in private within the five par-
ticipating services, were audio-recorded, and lasted
between 37 and 100 min. Each participant was given a
£20 shopping voucher at the end of their interview as a
gesture of thanks. The 36 participants included
26 men and 10 women, aged 24–63 years (mean
45 years). Most (n = 24) were White British and over
half (n = 21) reported that they were currently using
heroin. A quarter (n = 9) said that they had ever
received depot medication (contraception, anti-
psychotics or testosterone). Further participant details
are shown in Table 1.
The audio-recordings were transcribed verbatim and
the transcriptions were entered into the software pro-
gramme MaxQDA v11 [32] for systematic coding. A
coding frame was developed based on deductive codes
derived from the interview guide and inductive codes
emerging from the interview data. CT coded all the
interview data line-by-line to the coding frame. For
this paper, all data coded to the ‘information needs’
and ‘information preferences’ codes were exported
into separate Word documents and analysed by JN via
a process of Iterative Categorisation [33].
Analyses generated six categories of ‘information
need’: (i) medication purpose and availability;
(ii) pharmacology; (iii) evidence base and effectiveness;
(iv) safety and side effects; (v) administration and dos-
ing; and (vi) reducing and ending treatment. In addi-
tion, participants discussed their ‘information
preferences’ in terms of: (i) ‘information format’ and
(ii) ‘information source’. No notable differences
between the three groups of participants (daily pre-
scribed oral methadone, daily prescribed oral
buprenorphine and daily heroin use) were evident.
Findings are presented below using anonymised verba-
tim quotations to illustrate salient points.
Results
Information needs
Medication purpose and availability. Several partici-
pants asked why depot buprenorphine had been devel-
oped and questioned whether the intention was to
provide patients with more medication choice or sim-
ply to replace another medication. As one female par-
ticipant asked:
‘Are they going to stop the tablets and bring in an
injection?’ (participant 9, buprenorphine, female,
55 years)
Other participants questioned whether buprenorphine
depot injection was the same as buprenorphine tablets or
film and, if not, how it compared with other
buprenorphine products and with methadone. Some par-
ticipants also wanted to know when depot injections
would be available, how and where people could get one,
and whether there would be dosing options besides
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7 and 28 days. Furthermore, one person asked whether
people would be able to receive depot buprenorphine in
prison; explaining that he had previously had a negative
experience of withdrawal symptoms after his
buprenorphine treatment had been stopped in police
custody.
Pharmacology. Occasionally, participants requested
clarification on what exactly was in the injection and
whether the medication itself was in the form of an
injectable tablet or a liquid. More frequently, they
wanted to know whether it was mixed with an antago-
nist or ‘blocker’ (e.g. naloxone); whether it would
interact with other drugs, including prescribed pain
medications; or whether it contained sugar or other
ingredients that might damage their teeth or health
more generally:
‘Is there a lot of sugar in it? Is there stuff that can
cause liver damage?… It’s still nice to know what
you’re putting in you[rself]’. (participant 25, metha-
done, male, 41 years)
In terms of the medication’s mode of action, partici-
pants queried how the injection delivered the amount
of buprenorphine an individual patient needed; how it
substituted for heroin; how it released the
buprenorphine slowly; whether the buprenorphine
stayed local to the injection site or was absorbed into
the bloodstream; and how the medication was affected
by temperature, exercise, health status or individual
metabolism:
‘How does that work though? Because obviously
people’s metabolism is different… Like some people
will go through a medication quicker than other peo-
ple’. (participant 19, buprenorphine, male, 46 years)
In addition, one or two participants mistakenly
thought that the buprenorphine was dispersed into the
body at certain times of the day and wanted to know if
they would physically feel this occurring.
Evidence base and effectiveness. Few participants asked
whether depot buprenorphine had been tested on ani-
mals or humans, or whether it had been approved in
clinical trials or by regulatory authorities. Nonetheless,
most wanted to know how effective it was, especially in
terms of stopping heroin use, cravings and withdrawal
symptoms:
‘Once it’s in you, does this take away the urge to use
heroin?’ (participant 22, methadone, female,
50 years)
Table 1. Participant characteristics
Daily oral
methadone
(n = 12)
Daily oral
buprenorphine
(n = 12)
Daily heroin
(not in treatment)
(n = 12)
Total
(n = 36)
Sex
Male 8 (67%) 9 (75%) 9 (75%) 26 (72%)
Female 4 (33%) 3 (25%) 3 (25%) 10 (28%)
Age (years)
Mean (range) 40 (24–50) 47 (26–57) 47 (35–63) 45 (24–63)
Ethnicity
White/White British 10 (83%) 9 (75%) 5 (42%) 24 (67%)
Black/Black British 0 (0%) 2 (17%) 3 (25%) 5 (14%)
Asian/Asian British 1 (8%) 0 (0%) 0 (0%) 1 (3%)
Mixed or Multiple 1 (8%) 0 (0%) 2 (17%) 3 (8%)
Other 0 (0%) 1 (8%) 2 (17%) 3 (8%)
Current heroin use
Yes 6 (50%) 3 (25%) 12 (100%) 21 (58%)
No 6 (50%) 9 (75%) 0 (0%) 15 (42%)
Ever received depot medication
Yes – any 4 (33%) 2 (17%) 3 (25%) 9 (25%)
Yes – contraception 2 (17%) 1 (8%) 2 (17%) 5 (14%)
Yes – anti-psychotic medication 1 (8%) 1 (8%) 2 (17%) 4 (11%)
Yes – other 1 (8%)a 0 (0%) 0 (0%) 1 (3%)
No 8 (67%) 9 (75%) 9 (75%) 26 (72%)
Do not know 0 (0%) 1 (8%) 0 (0%) 1 (3%)
aTestosterone (intramuscular).
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Some participants also queried if the medication
would block the effects of any heroin taken; a few
asked if it would stop alcohol seizures; and several
were curious about how long the buprenorphine would
take to have an effect once administered. Routinely,
participants expressed concerns about what would
happen if it did not work, ‘ran out early’, or was not
effective for as long as the manufacturers promised:
‘I would want to know it will last that month…
because that would be the main concern… I don’t
want to get to say [day] 25, and on the 26th [day]
I’m feeling rough because the stuff has worn out of
your system’. (participant 3, heroin, male, 53 years)
Additionally, participants asked what would happen
if people decided to use alcohol or other drugs ‘on top
of’ the depot buprenorphine; particularly whether they
would feel intoxicated, experience withdrawal symp-
toms or overdose.
Safety and side effects. Repeatedly, participants asked
if depot buprenorphine was ‘safe’. For example, they
queried whether too much buprenorphine could be
released at once, whether patients could accidentally
overdose on it, or whether it could be wrongly admin-
istered into a vein:
‘If it went into the vein, which it shouldn’t be in the
vein, what’s the repercussions?’ (participant 32, her-
oin, male, 47 years)
Relatedly, participants questioned whether depot
buprenorphine was addictive or would cause unwanted
side effects. In this regard, they asked about scarring,
itching, pain, lumping or redness at the injection site,
but also nausea, headaches, constipation, mood
changes, dizziness, daytime tiredness, liver problems
and hair loss. Participants additionally expressed con-
cerns about potential changes in their weight, libido,
heart rate, blood pressure, clarity of thought, fertility,
appetite, and sleep, and one person wondered if
patients would be legally allowed to drive if they had
had a depot buprenorphine injection. Others asked
what would happen if patients had a bad reaction after
receiving an injection, and whether there was another
drug that could be administered to counter any
unintended negative effects:
‘Is there any way… it can be reversed?... Like when
people have overdoses, and then they reverse it. Are
there any ways, if any error were to happen… that
that can be [reversed]?’ (participant
2, buprenorphine, male, 45 years)
Administration and dosing. Although participants had
been told that the medication would be administered
by a healthcare professional, some still wanted to know
if it could be self-administered. Others queried how
the initial dose would be calculated; how much dose
would be released each day; and how patients would
feel at different times of the day, and from day to day,
including whether they would experience ‘a buzz’,
withdrawal symptoms, or mood swings:
‘Are you going to have mood swings because it
might not release as much that day as it did the day
before?’ (participant 25, methadone, male, 41 years)
Participants additionally questioned how the dose
could be changed if patients felt they were receiving
too much medication or not enough, and how long
would it take for any change in dosage to have an
effect. They also asked whether the dose received
would spike on the day after the injection and diminish
towards the end of the injection period, potentially
leaving them feeling unwell:
‘When it’s running out, do you feel like shit, a cou-
ple of days before you have to get your next injec-
tion?’ (participant 4, heroin, male, 53 years)
Reducing and ending treatment. Several participants
wanted to know whether depot buprenorphine was
intended as a maintenance medication and, if not, for
how long patients were expected to receive it. Others
asked how patients would ‘come off’ depot
buprenorphine, including how long coming off
would take:
‘I would want to know about how you would
reduce, how they go about reducing you’. (partici-
pant 22, methadone, female, 50 years)
Participants were also keen to know how severe the
withdrawal symptoms would be when a patient
stopped having depot buprenorphine injections, and
whether patients would crave more for opioids after
coming off depot medication because they would be
accustomed to having a constant dose of
buprenorphine in their body. Additionally, they won-
dered whether, and if so for how long, the
buprenorphine would remain in their system after the
injection had officially ended:
‘And when it comes to the end of 7 days, it’s going
to still be in your blood… Is that not right?’ (partici-
pant 20, buprenorphine, male, 56 years)
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Information preferences
Format. Participants frequently emphasised that it
would be necessary to have access to information on
depot buprenorphine in a range of formats because
patients have diverse needs and preferences. Reflecting
this, they described the importance of having printed,
verbal and electronic materials, and of enabling people
to access as little or as much information as they
wanted:
‘You’ve got to have a package… Some people [want]
video, some people are for leaflets, some people are
for oral… Some people can’t read… some people
can’t write. Some people would like to watch some-
thing… You would have to… do it in all different
ways to suit everybody’. (participant 6, heroin,
female, 42 years)
In terms of printed materials, participants expressed
a desire for leaflets, factsheets, newsletters and posters.
Whilst some liked the idea of receiving a written letter,
others said that they would prefer to read published
academic research. Some participants thought that
printed written material would be best as it could be
taken away, so enabling them to digest it, refer back to
it, and use it to make considered decisions about
whether depot buprenorphine was right for them per-
sonally. Others explained that they struggled to read
written materials due to poor eyesight or limited liter-
acy, or argued that written materials were old-
fashioned and could be dull and hard to follow:
‘Sometimes reading can be hard going, especially if
it’s not particularly what you want to hear, or you’re
not interested in it’. (participant 11, methadone,
male, 40 years)
Many participants explained that they would want
verbal information on buprenorphine depot injections
because it would be easier to ask questions. Moreover,
they thought that they would understand the medica-
tion better if somebody explained it to them in person.
Others liked the idea of participating in a group or
seminar where professionals and patients who had
already had depot buprenorphine told them about the
medication:
‘The right way to go would be maybe a small group,
five, ten people. Someone like yourself [researcher]
and then someone like myself. But I would have to
have… done so many months of it [depot
buprenorphine], so I know what I’m talking about’.
(participant 3, heroin, male, 53 years)
Although some participants cautioned that people in
opioid treatment do not tend to have computers,
others emphasised that the Internet is an important
source of information. Indeed, several participants
explained that they already used medical websites,
pharmaceutical websites, YouTube videos, and aca-
demic websites to research pharmaceutical drugs and
treatment. These participants said that they would
want to find out about depot buprenorphine by gather-
ing information online. Others expressed interest in
watching videos/DVDs of people who had had depot
buprenorphine talking about their experiences:
‘I mean maybe watching a video on someone that’s
actually done six months on it’. (participant
18, buprenorphine, male, 57 years)
Source. Participants consistently argued that informa-
tion on depot buprenorphine should come from people
who had ‘authority’ and could be ‘trusted’ because they
knew the medication. In this regard, they referred to
doctors, nurses, drug workers, counsellors, pharmacists,
researchers and pharmaceutical companies; although
some felt that pharmaceutical company information
might be biased and unreliable. Repeatedly, however,
participants emphasised that the best information source
would be people who had already had the medication
and could therefore speak from personal experience.
Participants argued that these individuals would be eas-
ier to talk to, more independent/truthful, and better able
to answer their questions. This, they said, would inspire
and reassure them if they were considering depot
buprenorphine for the first time:
‘I think you would get a better straight answer from
someone who’s been through it… They could give
you the bonuses… they could give you the disadvan-
tages… they can give you some idea as to what to
expect if they’ve been through it themselves’. (par-
ticipant 26, methadone, male, 44 years).
Discussion
People using opioids (both in and out of treatment)
had many questions about depot buprenorphine injec-
tions. For example, they wanted information on the
purpose and technology behind depot injections
(including why they had been developed and how they
worked) as well as on how depot MAT would person-
ally affect people who received it (by, for example,
reducing and stopping heroin use, craving and with-
drawal symptoms). These numerous questions are
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unsurprising given that opioid agonists are complex
multivalent drugs [34,35]; depot injections are multi-
faceted bio-delivery systems with uncertain outcomes
[19]; and extended release medications are a very new
way of providing MAT [20].
Participants’ requests for information on the avail-
ability of depot buprenorphine suggested that they
were potentially interested in receiving MAT via this
new delivery system. Nonetheless, questions relating to
safety, side effects and efficacy were prevalent. Some
questions (e.g. whether the medication contained
sugar or an antagonist) could be addressed relatively
easily within the standard patient information leaflet;
others (e.g. whether the medication would have long-
term side effects) might be difficult to answer with
confidence until further research has been completed.
Additionally, participants raised issues that drug man-
ufacturers might never be able to answer with certainty
(e.g. whether someone would be able to receive depot
buprenorphine in prison and how individuals would
feel from day to day).
Participants also wanted to know how depot
buprenorphine would compare with other forms of
MAT, thus indicating that they would want to weigh
up the pros and cons against more traditional options
[14]. Other participants asked how the buprenorphine
dose could be increased or decreased if their circum-
stances altered and, importantly, when and how
patients would be able to reduce and come off depot
treatment. In many ways, these findings are
unremarkable and parallel wider literature on being
prescribed drugs for chronic conditions; that is,
patients who take medication long-term worry about
side effects, the adverse impact on other aspects of
their lives, and feelings of loss of control [36–38].
Equally, the findings are consistent with prior research
that has shown how trust, perceptions of efficacy,
empowerment and control affect the uptake and use of
biomedical HIV prevention products [39] and how
lack of information and poor understanding can deter
people who inject drugs from engaging with hepatitis
C treatments [40].
The concept of the ‘informed patient’ has been
widely used in recent years and is underpinned by an
assumption that patients take responsibility for their
health and actively seek out medical information, often
by the Internet [29,41,42]. Consistent with this idea,
participants in the study wanted information in a range
of formats and some said that they would proactively
look for information online. Nonetheless, others
referred to limited ability to read, little interest in long
documents, and poor access to computers. Further-
more, most wanted and expected information to be
provided ‘to them’. Socio-demographic factors
(e.g. limited education, low income and poor health)
impede proactive health information seeking [43] and
are also common amongst people who use non-
prescribed opioids [44,45]. It is therefore important
that accessible information is routinely ‘offered to’ all
potential depot injection patients to avoid com-
pounding any pre-existing knowledge inequalities.
Using health information can, meanwhile, empower
members of marginalised communities as it enables
them to discuss their treatment options within the doc-
tor/ patient encounter and even challenge medical
opinion [29,41–43]. Study participants expressed a
desire for information provided by healthcare profes-
sionals, scientists, and drug developers; even though
there was some skepticism about the independence of
information provided by pharmaceutical companies.
Importantly, however, participants consistently wanted
to hear the views and experiences of people with lived
experience of depot buprenorphine; in other words,
they often prioritised ‘lay knowledge’ over more formal
‘biomedical knowledge’ [41,46]. Providing people who
use opioids with access to information based on the
lived experience of people receiving depot
buprenorphine could help potential patients engage
more fully in discussions about this new medication.
Moreover, patient-centred care and shared decision
making might increase if doctors were also able to lis-
ten to, and learn from, the personal accounts of actual
patients [14,47].
Limitations
The analyses presented derive from qualitative inter-
views conducted with 36 people using opioids from
one UK city. Discussions were largely based around
the concept of two depot buprenorphine products
(CAM2038/ Buvidal® Weekly and Buvidal® Monthly);
non-English speakers were not interviewed; and those
who agreed to participate were a self-selecting group
who may have had a particular interest in
buprenorphine depot injections (we note that nine of
36 had already had a depot injection). As such, we
cannot draw any empirical generalisations from our
findings. Despite this, the frequency with which partic-
ipants reported similar questions and opinions on
information formats and sources suggests that these
findings are likely to be replicated in other opioid
using samples and with respect to other depot
buprenorphine products. We did not identify any nota-
ble differences between the three groups (people pre-
scribed methadone daily, people prescribed
buprenorphine daily, and people using heroin daily),
but this might relate to the relatively small number of
study participants. Additionally, information needs
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and preferences might vary more significantly
according to other socio-demographic characteristics
(e.g. sex, age, race, education, housing status) and this
could be explored in a future larger study.
Conclusion
People who use opioids are likely to have many ques-
tions about new depot buprenorphine injection formu-
lations and will want authoritative information in a
range of formats (and languages). As with any medica-
tion, it will be difficult to predict which questions any
individual patient may have and impossible to answer
all questions definitively. That said, potential patients
will almost certainly want to know how the medication
compares with alternative medications, how it delivers
buprenorphine, how it can help those with opioid use
disorder, whether it is safe and has side effects, how
they can access it, how it will make them feel, and
when and how they can come off it.
Despite increasing global use of the Internet and
electronic media, simple leaflets and verbal explana-
tions still appear to be essential information sources
for people who use opioids. A leaflet that includes
basic factual information, personal accounts of patients
who have had depot buprenorphine, and links to more
comprehensive scientific research would enable people
to access as much or as little information as they
wanted. We also recommend that an independent pro-
spective, longitudinal, qualitative study exploring how
patients experience depot buprenorphine injections
over a period of months and years is needed. Findings
from this research should be published in academic
journals but additionally turned into an accessible
online video resource (precedents for this include:
http://www.healthtalk.org/ and https://www.
livesofsubstance.org/). Potential patients could then be
signposted to watch the video material at home and
invited to view it in treatment services. Equally, it
could function as a training tool for doctors. The
patient-focused nature of the content would help to
balance biomedical knowledge with lay knowledge, so
facilitating more informed discussions when decisions
about depot buprenorphine treatment are made
[14,46,47].
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